NewTimeSpace News: On 28 August 2026, HAIER SMARTHOME (06690.HK) announced that Vice Presidents Wu Yong and Huang Decheng resigned effective 27 August 2026 due to work changes, remaining in other positions at the Company.
NewTimeSpace News: On 27 August 2026, DUALITYBIO-B (09606.HK) announced a collaboration and license agreement with Roche's Genentech to develop next-generation ADCs based on its DUPAC platform, with an upfront payment of USD 45 million and eligibility for milestone payments exceeding USD 1.0 billion plus tiered royalties.
NewTimeSpace News: On 28 August 2026, JIANGSU EXPRESS (00177.HK) announced Board approval of a RMB 600 million capital injection into its clean energy subsidiary, to be paid over five years (RMB 40 million expected in 2026), raising its registered capital from RMB 2.0 billion to RMB 2.6 billion, with proceeds for fishery/crab-pond photovoltaic and wind power projects.
NewTimeSpace News: On 27 August 2026, SIHUAN PHARM (00460.HK) announced that, pursuant to the general buyback mandate, it repurchased 10,000,000 shares at an average price of HKD 0.8111 per share, for a total of approximately HKD 8.111 million, representing approximately 0.1096% of issued shares (excluding treasury) and to be held as treasury shares; the Group reported H1 2026 revenue of RMB 1.161 billion (up 1.3%) and net profit of RMB 212 million (up 221%), with medical aesthetics revenue of RMB 693 million (up 18.5%).
NewTimeSpace News: On 27 August 2026, CHINA VANKE (02202.HK) announced that, from 1 March 2026 to 31 July 2026, the Company and its controlling subsidiaries recorded newly unsettled litigation and arbitration matters involving approximately RMB 12.041 billion, equivalent to 10.30% of the absolute value of the latest audited net assets; four cases each exceeded RMB 300 million, totaling RMB 4.050 billion, and the impact of some cases on the Company's profits remains uncertain.
NewTimeSpace News: On 27 August 2026, GUSHENGTANG (02273.HK) announced that its subsidiary Gushengtang Malaysia has entered into sale and purchase contracts to acquire the 100% equity interests of three TCM medical institutions in Malaysia (YC TCM SEGAR, YC TCM and SWS Medical) to expand its overseas offline network and create synergies; the consideration was determined after fair negotiation and will be funded by placing/convertible bond proceeds and idle funds; the acquisition does not constitute a connected or discloseable transaction and is subject to conditions precedent.
NewTimeSpace News: On 27 August 2026, DRAGON RISE GP (06829.HK) voluntarily announced that its wholly-owned subsidiary DRNE Next Mobility has entered into an agreement with a blockchain service provider to issue tokenized notes secured by physical assets (battery-swap electric taxi fleet and income from swap infrastructure) on Ethereum and Solana; the reserved quota is HKD 100 million with an initial tranche cap of HKD 30 million, a minimum subscription of HKD 400,000, a two-year lock-up, and a target return of 4% fixed interest plus up to 6% performance-linked interest per annum.
NewTimeSpace News: On 27 August 2026, XIABUXIABU (00520.HK) announced that Mr. He Guangqi will step down as CEO and be re-designated from executive to non-executive director with effect from 28 August 2026, continuing as Chairman with an annual director's fee of HKD 1,220,000; Mr. Feng Huihuang will succeed him as CEO with annual remuneration of RMB 984,000, temporarily also holding the finance role; the change brings the Company into compliance with Code Provision C.2.1.
NewTimeSpace News: On 27 August 2026, ABLE DIGITAL (02687.HK) announced that the Board has approved the proposed H-share full circulation, converting 4,713,900 domestic unlisted shares held by shareholders into H shares, representing approximately 7.0708% of the issued share capital; the conversion remains subject to CSRC filing and HKEX approval, no general meeting is required, and the Company has not yet submitted the filing application.
NewTimeSpace News: On 27 August 2026, TYK MEDICINES-B (02410.HK) announced that its self-developed next-generation EGFR-TKI dovatinib mesylate tablets (TY-9591) have been granted conditional NMPA approval for the first-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR 19del or L858R mutations with CNS metastases; the drug is a differentiated deuterated innovation derived from osimertinib, and the Company has initiated multiple monotherapy and combination studies around the product.
NewTimeSpace News: On 27 August 2026, ZHENRO SERVICES (06958.HK) announced the appointment of Mr. Wang Yi, aged 44 and currently the Company Secretary and CFO, as an executive director with effect from the same day, with the appointment lasting until the conclusion of the next annual general meeting and a basic salary of RMB 680,000 per annum.
NewTimeSpace News: On 27 August 2026, IMMUNEONCO-B (01541.HK) announced that the first patient has been dosed in the Phase II trial (IMM2510-HCC-201) of IMM2510 plus IMM27M as first-line treatment for advanced HCC; the Phase Ib trial has determined the RP2D with expansion studies in esophageal squamous cell carcinoma and other solid tumors, and 6 evaluable patients in dose escalation achieved an ORR of 50%; the combination achieves synergistic coverage of PD-L1, VEGF and CTLA-4, with a Rule 18A.05 warning statement included.
NewTimeSpace News: On 27 August 2026, COOLPAD GROUP (02369.HK) announced that its wholly-owned subsidiary Digital Tech sold 248 call options covering 24,800 MSTR shares for a total premium of USD 71,442 (approximately HKD 557,962), with a strike price of USD 140.00 per share and expiry on 11 September 2026; if all options are exercised, the Group expects to recognize a gain of approximately USD 1.16 million, and the sale constitutes a discloseable transaction exempt from shareholders' approval.
NewTimeSpace News: On 27 August 2026, SHIMAO GROUP (00813.HK) announced that Guotong Trust had filed a winding-up petition against the Company with the High Court, relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts, with the first hearing fixed for 11 November 2026; no winding-up order has been issued, the Company will resolutely oppose the petition, and the announcement cautioned on the effects of Section 182 of the Companies Ordinance and potential HKSCC service suspensions.
NewTimeSpace News: On 27 August 2026, SHIMAO SERVICES (00873.HK) announced that its holding company Shimao Group had received a winding-up petition filed by Guotong Trust relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts; no winding-up order has been issued by the High Court, and the Board believes the petition will have no material impact on the Group's financial performance and operations.
NewTimeSpace News: On 27 August 2026, FOSUN PHARMA (02196.HK) announced that GR1803 injection (weliteitumab injection; trade name Weikenuo), licensed by its controlling subsidiary Yaoyou Pharmaceutical, has been granted conditional NMPA approval for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy; the drug is a BCMA×CD3 bispecific antibody in a 20mg (2ml) per vial specification classified as Class 1 therapeutic biologics, with global sales of same-target drugs reaching approximately USD 1.139 billion in 2025, and an MAH transfer will subsequently be advanced.
